Skip to Content



PDF options:  View Fullscreen   Download PDF

PDF Transcript


Methylprednisolone 40 mg, 500 mg and 1000 mg
Powder for solution for injection
Methylprednisolone (as sodium succinate)

• myasthenia gravis (a muscle weakening disease)
Read all of this leaflet carefully before you start using this medicine
• underactive thyroid gland (hypothyroidism)
because it contains important information for you.
• Kaposi’s syndrome (a type of skin cancer).
• Keep this leaflet. You may need to read it again.
• If you have any further questions, ask your doctor or nurse.
This medicine has been prescribed for you only. Do not pass it on to others. It may Before you have any operation tell your doctor, anaesthetist or dentist that you
are being treated with methylprednisolone as your body’s reaction to stress is
harm them, even if their signs of illness are the same as yours.
• If you get any side effects, talk to your doctor or nurse. This includes any possible
side effects not listed in this leaflet. See section 4.
If you require a test to be carried out by your general practitioner or hospital you
must tell the doctor that you are being treated with methylprednisolone as this
1. What Methylprednisolone is and what it is used for
medicine could affect the test results.
2. What you need to know before you use Methylprednisolone
3. How to use Methylprednisolone
Other medicines and Methylprednisolone
4. Possible side effects
Tell your doctor or nurse if you are taking, have recently taken or might take any
5. How to store Methylprednisolone
other medicines.
6. Contents of the pack and other information
Some medicines could be harmful if taken with methylprednisolone, or could affect
the way either methylprednisolone or the other medicine works. Your doctor may
need to adjust the dose of your medicine if you are taking other medicines.

Methylprednisolone is the active substance of Methylprednisolone powder for
solution for injection.
Methylprednisolone contains Methylprednisolone Sodium Succinate.
Methylprednisolone belongs to a group of medicines called corticosteroids
(steroids). Corticosteroids are produced naturally in your body and are important for
many body functions.
Boosting your body with extra corticosteroid such as Methylprednisolone can help
following surgery (e.g. organ transplants), flare-ups of the symptoms of multiple
sclerosis or other stressful conditions.
Methylprednisolone may be used to treat the following diseases:
Allergic conditions:
Bronchial, asthma.
Acute throat oedema of non-infectious origin.
Severe perennial allergic rhinitis.
Swelling of the mouth, the tongue and the trachea, which can cause difficulty in
breathing (angioneurotic oedema).
Very serious allergic reaction (anaphylaxis).
Skin disorders:
Severe inflammatory diseases of the skin.
Critical phases of gastro-intestinal diseases:
Inflammation of the large bowel and inflammation of the small bowel (Crohn’s
Neurological disorders:
In certain cases of brain swelling, acute spinal cord injuries, worsening or flare-up
of sclerosis multiplex.
Respiratory diseases:
Aspiration of gastric contents.
Severe inflammatory diseases affecting the lung.

Tell your doctor or nurse if you are taking any of the following:
• acetazolamide for glaucoma, epilepsy and water retention
• aminoglutethimide for Cushing’s syndrome and breast cancer
• antibiotics: rifampicin, rifabutin, troleandomycin or erythromycin
• anticoagulants such as warfarin, acenocoumarol and phenindione used to thin the
blood. Your doctor may perform blood tests to make sure that your blood clotting
is normal
• aspirin, sodium salicylate and non-steroidal anti-inflammatory drugs such as
ibuprofen, naproxen and diclofenac used to treat mild to moderate pain
• carbamazepine for epilepsy, pain and manic depression
• antipsychotics
• carbenoxolone for stomach ulcers and heartburn
• ciclosporin to prevent organ rejection
• cimetidine for stomach ulcers and heartburn
• diltiazem and mibefradil for problems of the heart and blood circulation such as
high blood pressure and angina
• digoxin and similar heart glycosides
• diuretics for water retention such as hydrochlorothiazide, furosemide and
etacrynic acid
• methotrexate
• insulin and other drugs such as metformin for diabetes. If you have diabetes, you
may need to check your blood sugar more closely when using methylprednisolone
• ketoconazole and itraconazole for fungal infections
• salbutamol
• medicines for high blood pressure such as lisinopril and losartan
• pancuronium or other medicines used for muscle relaxation during surgery and
tooth extractions
• phenobarbital, phenytoin and primidone for epilepsy
• pyridostigmine and neostigmine for myasthenia gravis
• vaccinations: tell your doctor before being immunised with live vaccines such as
for polio if you are taking or have been taking corticosteroids as there is a risk of
infection and poor immune response to the vaccine.
Pregnancy and breast feeding
If you are pregnant or breast-feeding, think you may be pregnant or are planning to
have a baby, ask your doctor nurse for advice before using this medicine.

Other diseases:
In certain cases of meningitis caused by the pathogen responsible for tuberculosis.
To reduce the reactions of the immune system in case of organ transplantation.
You must talk to a doctor if you do not feel better or if you feel worse.

You will be given this medicine during pregnancy and breastfeeding only if the
doctor assesses that the benefit from the treatment is greater than the possible
risks to the embryo/foetus or infant.
There is no evidence that corticosteroids would impair fertility.
Methylprednisolone contains sodium
Each vial of Methylprednisolone 40 mg contains less than 1 mmol sodium (23mg)
per 40mg, i.e. essentially “sodium-free”.

Do not use Methylprednisolone:
• If you are allergic to methylprednisolone (or any other corticosteroid) or any of the
other ingredients of this medicine (listed in section 6).
• if you have a fungal infection, other than on the skin, which is not being treated.
• you have ever had fever, fits and loss of consciousness linked with malaria
(cerebral malaria).
• you are suffering from a head injury or stroke.
Warnings and precautions
Talk to your doctor or nurse before using Methylprednisolone.

Each vial of Methylprednisolone 500 mg contains 53.18mg sodium per 500mg.
Each vial of Methylprednisolone 1000 mg contains 167.59mg sodium per 1000mg.
If you are on controlled sodium (salt) diet tell your doctor in case your sodium intake
needs to be adjusted.


Tell your doctor or nurse immediately if any of the following apply to you:
• you have not had chicken pox, measles, shingles or a herpes eye infection. If you
develop them when taking methylprednisolone they could make you very ill. If you
are not immune or you are a parent of a child receiving this medicine, avoid close
contact with anyone with these infections. Seek immediate medical advice if you
think you have been exposed to one of these infections or if a member of your
household develops one of them.
• you are being treated with digoxin (a medicine for heart failure).
You must tell your doctor before Methylprednisolone is given if you suffer
• brittle bones (osteoporosis) or if you are a woman who has gone through the
• mood disorders, either currently or in the past, including severe depression,
manic-depression (bipolar disorder), or problems such as delusions, hallucinations
or disorganised speech after taking steroids
• high blood pressure (hypertension)
• weakness of the heart muscle (heart failure)
• a recent heart attack
• diabetes, either in you or close family. If you have diabetes, you should closely
monitor blood sugar while taking methylprednisolone
• tuberculosis, either currently or in the past
• glaucoma, either in you or close family
• pain or weakness in the muscles after treatment with corticosteroid medicines in
the past
• liver problems such as jaundice
• poor kidney function
• epilepsy
• an ulcer in the small intestines
• recent fistula (abnormal connections inside the intestines)
• ulcerative colitis and diverticulitis (disorders of the gut)
• inflammation and blood clots of the leg veins (thrombophlebitis)
• skin abscesses

Steroid Cards
Remember to always carry a Steroid Treatment Card. Make sure your doctor
or pharmacist has filled out the details of your medicine, including the dose
and how long you will require steroid treatment.
The recommended dose is:
The initial dose is usually 10-500 mg depending on the disease treated. Larger
doses may be required for short-term management of severe, acute conditions.
The initial dose, up to 250 mg, should be given intravenously as a bolus injection
over a period of at least 5 minutes, doses exceeding 250 mg should be given as an
infusion over a period of at least 30 minutes.
You will normally receive the same treatment as younger adults although the doctor
may decide to check the side effects of treatment more closely (see Section 4).
Use in children
In infancy, childhood and adolescence, corticosteroids may cause growth to be
slowed down. This may be irreversible. Your doctor should limit treatment to the
minimum dose for the shortest period of time.
If you use more Methylprednisolone than you should
If you think you have been given too many injections please speak to your doctor
Stopping/reducing the dose of your Methylprednisolone
Your doctor will decide a suitable time to stop treatment.
The dose should be gradually reduced if:
• you have been treated with corticosteroid injections for more than 3 weeks
• it has been less than one year since you stopped long-term treatment (months or
years) with corticosteroid tablets

Methylprednisolone 40 mg, 500 mg and 1000 mg
Powder for solution for injection
Methylprednisolone (as sodium succinate)

The following information is intended for medical or healthcare professionals only:
Method of administration:
Methylprednisolone may be administered intravenously or intramuscularly, the
preferred method for emergency use being intravenous injection given over a suitable
time interval.


Solvent quantity

Final solution

40 mg

1.2 ml

40 mg/ml

125 mg

2.1 ml

62.5 mg/ml

250 mg

4 ml

62.5 mg/ml

a) Preparation of solution for injection (reconstitution):

500 mg

8 ml

62.5 mg/ml

Methylprednisolone solution for injection should be prepared by dissolving the powder
in an appropriate volume of water for injection, as shown in the table.

1000 mg

16 ml

62.5 mg/ml

• you

suffer from Addison’s disease or conditions where your adrenal glands do not
produce enough natural corticosteroids
• you have had a course of more than 32mg of methylprednisolone each day
• your injections were in the evening.
It is important to reduce the dose gradually to avoid withdrawal symptoms.
Withdrawal symptoms may include:
• itchy skin
• sweating
• fever
• muscle and joint pains
• runny nose
• sticky eyes
• weight loss.
If your symptoms return or get worse as your medicine is reduced tell your doctor
Mental health problems while using Methylprednisolone
Mental health problems can happen while taking steroids like methylprednisolone
(see also Section 4). Corticosteroids, especially with high doses, can alter your
mood and behaviour. Some patients become confused, irritable and suffer from
delusions and suicidal thoughts early in treatment. This is particularly the case if
you are already suffering or susceptible to mental problems. These effects can also
occur when stopping methylprednisolone. Speak to a doctor if you or someone
close to you is worried by psychological changes.

Like all medicines, this medicine can cause side effects, although not everybody
gets them.
Methylprednisolone is used for illnesses that could get worse if not properly treated.
Side-effects are more likely at high doses or during prolonged treatment. Your
doctor will prescribe the lowest effective dose for the shortest possible time to
minimise side-effects. Ask your doctor if you need any further advice.
Serious side effects
Contact your doctor IMMEDIATELY if you get any of the following symptoms:
• sudden life-threatening allergic reaction (anaphylaxis) with symptoms such as
rash, itching or hives on the skin, swelling of the face, lips, tongue or other parts
of the body, shortness of breath, wheezing or breathing difficulties
• infections, which may be more frequent and severe, although symptoms may be
less obvious
• stomach ulcers which may lead to perforation and bleeding. Symptoms are
stomach pain, black tarry stools or vomiting blood
• acute pancreatitis causing severe pain in the abdomen and across the back
• increased pressure in the skull (pseudotumor cerebri) in children, usually after
stopping methylprednisolone. Symptoms are headache with vomiting, lack of
energy and drowsiness
• blood clots in the veins (thromboembolism), which may produce pain, tenderness
or swelling in one leg; or of the lungs with symptoms of sudden sharp chest pain,
breathlessness and coughing up blood
• failure of the heart to pump blood properly leading to severe breathlessness and
swollen ankles (congestive heart failure).
Other side effects
Tell your doctor if any of the following become serious:
Effects on the blood and lymphatic system:
• increase of white blood cells (this side effect has been reported with frequency
not known, i.e. cannot be estimated from the available data).
Effects on the digestive system:
• indigestion, bloating, fungal infections or ulcers of the gullet
• feeling sick, vomiting and bad taste in the mouth
• methylprednisolone can damage your liver, hepatitis and increase of liver
enzymes have been reported (these side effects have been reported with
frequency not known, i.e. cannot be estimated from the available data).
Effects on the immune system:
• increased susceptibility to infections
• some skin tests may give abnormal results and inactive tuberculosis could return.
Effects on bones, muscles and joints:
• weakness of the muscles in the shoulder and hips
• thinning of the bones (osteoporosis) and bone fractures especially of the spine,
arms and legs. Bone thinning usually requires additional treatment (particularly if
you are a woman over 60) in order to prevent breakages and fractures
• loss of blood supply to the bones in the joints may lead to pain in the knee and
• torn muscle tendons causing pain or swelling.
Effects on kidney function:
• retention of sodium and water, loss of potassium possibly resulting in abnormal
blood alkalinity, which in rare cases can lead to congestive heart failure (see
serious side effects).
Effects on the skin:
• development of pale or dark areas of skin
• slow wound healing, pinhead spots under the skin and bruising, redness, thinning
of the skin, stretch marks, acne. Kaposi’s sarcoma (a type of skin cancer). These
effects may get better if the dose of your medicine is reduced.
Hormonal effects:
• reduced activity of the hypothalamus, pituitary and adrenal glands which control
reactions to stress, digestion, the immune system and emotions
• slow growth in infants and children
• problems with your periods (menstruation)
• rounded (moon-shaped) face typical of Cushing’s syndrome
• excessive hairiness
• reduced ability to process sugars and starches with increased need for treatment
with diabetes medication
• loss of muscle and bone
• increased appetite and weight gain.
Metabolism and nutrition effects:
• accumulation of fat tissue on localized parts of the body.

Changes to your mental state:
Steroids including methylprednisolone can cause serious mental health problems.
These reactions are common in both adults and children. About one in twenty
adults may be severely affected.
• mood changes such as irritability, extreme happiness (euphoria), depression and
sudden mood swings, withdrawal symptoms including anxiety
• suicidal thoughts
• delusions, hallucinations, mania, worsening of schizophrenia
• behavioural disturbances, sleep disturbances, fits (seizures)
• problems with poor mental function including confusion and memory loss.
Effects on the eye:
• raised pressure in the eye, glaucoma
• swelling of the optic nerve leading to possible damage
• blurred vision or difficulty seeing (cataracts), thinning of the cornea and whites of
the eye
• worsening of existing viral or fungal eye infections
• disease of the retina and choroid membrane (this side effect has been reported
with frequency not known, i.e. cannot be estimated from the available data).
Effects on the heart, lung and blood circulation:
• tearing of the heart muscles following a heart attack
• high blood pressure which may give you headaches, or make you feel generally
• sudden drop in blood pressure leading to collapse
• heart attack
• irregular heart beat
• raised levels of white blood cells
• wheezing or coughing
• increased clotting of the blood (this side effect has been reported with frequency
not known, i.e. cannot be estimated from the available data).
Effects on your nervous system:
• convulsions and increased pressure in the head.
Other effects:
• persistent hiccupping, feeling unwell.
Withdrawal symptoms
A ‘withdrawal syndrome’ may occur, see Section 3 for more information.
Reporting of side effects
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes
any possible side effects not listed in this leaflet. You can also report side effects
directly via the Yellow Card Scheme at:
By reporting side effects you can help provide more information on the safety of this

Keep this medicine out of the sight and reach of children.
Store below 25°C.
Keep the vial in the outer carton in order to protect from light.
Do not use this medicine after the expiry date which is stated on the vial’s label and
carton after EXP. The expiry date refers to the last day of that month.

What Methylprednisolone contains

• The active substance is methylprednisolone (as sodium succinate).
• The other ingredients are sodium dihydrogen phosphate dihydrate, disodium
phosphate anhydrous and sodium hydroxide. The 40 mg vial also contains
What Methylprednisolone looks like and contents of the pack
Methylprednisolone is a white or nearly white powder, packed in a clear glass vial
closed with a rubber stopper and a flip-off aluminium capsule.
Each vial of Methylprednisolone 40 mg contains 53.0 mg of methylprednisolone
sodium succinate, equivalent to 40 mg of methylprednisolone.
Each vial of Methylprednisolone 500 mg contains 663.0 mg of methylprednisolone
sodium succinate, equivalent to 500 mg of methylprednisolone.
Each vial of Methylprednisolone 1000 mg contains 1,326.0 mg of
methylprednisolone sodium succinate, equivalent to 1000 mg of
Marketing Authorisation Holder and Manufacturer
Hikma Farmacêutica (Portugal), S.A.
Estrada do Rio da Mó 8, 8A e 8B – Fervença
2705-906 Terrugem SNT
Distributed by:
Consilient Health (UK) Ltd.
No. 1 Church Road, Richmond upon Thames,
Surrey, TW9 2QE
This medicinal product is authorised in the Member States of the EEA
under the following names:
Czech Republic:






United Kingdom:

Methylprednisolone Hikma, 40mg, 125mg, 250mg, 500mg a
1000, Prášok na injekený
ˇ roztok
Méthylprednisolone Hikma, 40mg, 500mg et 1000mg, Poudre
pour solution injectable
Methylprednisolone Hikma, 250mg und 1000mg, Pulver zur
Herstellung einer Injektionslösung
Metilprednisolone Hikma, 40mg, 125mg, 500mg e 1000mg,
Polvere per soluzione iniettabile
Metilprednisolona Hikma, 40mg, 125mg, 250mg, 500mg e
1000mg, Pó para solução injetável
Methylprednisolone Hikma, 40mg, 125mg, 250mg, 500mg e
1000mg, Prášok na injekený
ˇ roztok
Methylprednisolone, 40mg, 500mg and 1000mg, Powder for
solution for injection

This leaflet was last revised in April 2016



b) Preparation of infusion solution
For intravenous infusion the initially prepared solution may be diluted with 5%
dextrose in water for injection, 0.9% Sodium Chloride in water for injection (isotonic
saline solution), or 5% dextrose in isotonic saline solution. To avoid compatibility
problems with other drugs Methylprednisolone should be administered separately,
only in the solutions mentioned.
Parenteral drugs products should be inspected visually for particulate matter and
discoloration prior to administration.

After reconstitution as recommended, use immediately, discard any remainder.
From a microbiological point of view, the product should be used immediately. If not
used immediately, in-use storage times and conditions prior to use are the
responsibility of the user and would normally not be longer than 24 hours at 2º to 8ºC,
unless reconstitution/dilution has taken place in controlled and validated aseptic
Any unused medicinal product or waste material should be disposed of in accordance
with local requirements.

+ Expand Transcript

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.